EUVIMEDEUVIMED entdecken
Open Access

Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis

Liene Friebe, Martin T Freitag, Martin Braun, Guillaume Nicolas, Andreas Bauman, David Bushnell, Emanuel Christ, Damian Wild

Journal of Nuclear Medicine · 2024-02 · 65 (2) · 228-235

DOI: 10.2967/jnumed.123.265894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 21.12.2023. Verfasst von Liene Friebe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Insulinoma, Neuroendocrine Tumors, Pancreatic Neoplasms, Hypoglycemia. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic insulinoma is a rare malignant neuroendocrine tumor characterized by inappropriate insulin secretion, resulting in life-threatening hypoglycemia, which is often difficult to treat. There is currently very limited information about the efficacy of peptide receptor radionuclide therapy (PRRT) for clinical control of hypoglycemia. The aim of this long-term retrospective study was to evaluate the therapeutic efficacy of PRRT for improving hypoglycemia, to evaluate the change of medication after PRRT, and to calculate progression-free survival (PFS) and overall survival (OS).

Methods

Inclusion criteria were histologically proven somatostatin receptor-positive metastatic malignant insulinoma and at least 2 cycles of [90Y]Y-DOTATOC or [177Lu]Lu-DOTATOC therapy from early 2000 to early 2022. A semiquantitative scoring system was used to quantify the severity and frequency of hypoglycemic episodes under background antihypoglycemic therapy (somatostatin analog, diazoxide, everolimus, corticosteroids): score 0, no hypoglycemic episodes; score 1, hypoglycemic events requiring additional conservative treatment with optimization of nutrition; score 2, severe hypoglycemia necessitating hospitalization and combined medication or history of hypoglycemic coma. Hypoglycemic score before and after PRRT was analyzed. Time of benefit was defined as a time range of fewer hypoglycemic episodes in the observation period than at baseline. Information on antihypoglycemic medication before and after therapy, PFS, and OS was recorded.

Results

Twenty-six of 32 patients with a total of 106 [90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC cycles were included. The average observation period was 21.5 mo (range, 2.3-107.4 mo). Before therapy, 81% (n = 21) of the patients had a hypoglycemia score of 2 and 19% (n = 5) had a score of 1. After PRRT, 81% of patients (n = 21) had a decreased score, and the remaining 5 patients showed a stable situation. There was temporary worsening of hypoglycemia just after injection of [90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC in 19% of patients. The average time of benefit in the observation period was 17.2 mo (range, 0-70.2 mo). Antihypoglycemic medication reduction was achieved in 58% (n = 15) of patients. The median OS and PFS after the start of PRRT were 19.7 mo (95% CI, 6.5-32.9 mo) and 11.7 mo (95% CI, 4.9-18.5 mo), respectively.

Conclusion

To our knowledge, our study included the largest cohort of patients with malignant insulinoma to be evaluated. Long-lasting symptom control and reduction of antihypoglycemic medications were shown in most patients after late-line PRRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InsulinomaNeuroendocrine TumorsPancreatic NeoplasmsHypoglycemiaOrganometallic CompoundsHumansRetrospective StudiesTreatment OutcomeOctreotideRadioisotopesReceptors, PeptideHypoglycemic Agents

Stichwörter der Autor:innen

PRRT[177Lu]Lu-DOTATOC[90Y]Y-DOTATOCmalignant insulinoma

Substanzen

OctreotideRadioisotopesReceptors, PeptideHypoglycemic AgentsOrganometallic Compounds

Autor:innen und Institutionen

  • Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
  • ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland.
  • Clinic of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany.
  • Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa; and.
  • Department of Endocrinology, Diabetology, and Metabolism, University Hospital Basel, Basel, Switzerland.
  • Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland; damian.wild@usb.ch.

Förderung

  • NCI NIH HHS

Zitieren

APA

Friebe, L., Freitag, M. T., Braun, M., Nicolas, G., Bauman, A., Bushnell, D., Christ, E., & Wild, D. (2024). Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis. Journal of Nuclear Medicine, 65(2), 228-235. https://doi.org/10.2967/jnumed.123.265894

Vancouver

Friebe L, Freitag MT, Braun M, Nicolas G, Bauman A, Bushnell D, et al. Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis. Journal of Nuclear Medicine. 2024;65(2):228-235. doi:10.2967/jnumed.123.265894

BibTeX
@article{Friebe2024,
  author = {Friebe, Liene and Freitag, Martin T and Braun, Martin and Nicolas, Guillaume and Bauman, Andreas and Bushnell, David and Christ, Emanuel and Wild, Damian},
  title = {Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {2},
  pages = {228--235},
  doi = {10.2967/jnumed.123.265894}
}
Kostenlos starten →